NCT01128881已完成4 期
IMMUNINE - Purified Factor IX Concentrate Virus-Inactivated: A Phase 4, Prospective, Open-label Multicenter Study to Prospectively Document the Exposure of IMMUNINE and to Monitor FIX Inhibitors in Previously Treated Patients With Severe (FIX Level < 1%) or Moderately Severe (FIX Level <= 2%) Hemophilia B Who Are Planned to Enter BAX 326 Study 250901 to Investigate a New Recombinant FIX Concentrate
Baxalta now part of Shire33 个研究点 分布在 11 个国家目标入组 57 人开始时间: 2010年5月31日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 57
- 试验地点
- 33
- 主要终点
- Hemostatic Efficacy
研究概览
简要总结
The primary objective of this study is to prospectively document the exposure to IMMUNINE and to monitor FIX inhibitors over a period of approximately 20 to 50 exposure days while receiving prophylactic treatment in up to 50 previously treated patients (PTPs) aged 12-64 years and approximately 20 pediatric PTPs up to 11 years of age with severe (FIX level < 1%) or moderately severe (FIX level <= 2%) hemophilia B who are planned to enter BAX326 study 250901, provided all eligibility criteria are met.
In addition, this study will evaluate the efficacy, safety, immunogenicity, thrombogenicity, and health-related quality of life (HR QoL) of these subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- — 至 64 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is up to 64 years old at the time of screening
- •Subject and/or legal representative has/have provided signed informed consent
- •Subject has severe (FIX level < 1%) or moderately severe (FIX level <= 2%) hemophilia B (based on the one stage activated partial thromboplastin time (aPTT) assay), as tested at screening at the central laboratory
- •Subject is previously treated with plasma-derived or recombinant FIX concentrate(s), cryoprecipitate or fresh frozen plasma (FFP) for approximately 100-150 exposure days (EDs) if >= 6 years old, or 20-50 EDs if < 6 years old, and is planned to enter BAX326 study
- •The number of EDs are derived from the subject's treatment regimen and his/her bleeding pattern
- •Subject is willing to receive prophylactic treatment for the duration of the study
- •Subject is immunocompetent as evidenced by a CD4 count >= 200 cells/mm(3)
- •Subject is human immunodeficiency (HIV) negative or is HIV+ with a viral load < 200 particles/μL ~ < 400,000 copies/mL
- •Female subject of childbearing potential, presents with a negative serum pregnancy test, and agrees to employ adequate birth control measures for the duration of the study
- •Subject is willing and able to comply with the requirements of the protocol
排除标准
- •The subject has a detectable factor IX inhibitor at screening, with a titer >= 0.6 Bethesda Units (BU) as determined by the Nijmegen modification of the Bethesda assay in the central laboratory
- •The subject has a history of factor IX inhibitors with a titer >= 0.6 BU (as determined by the Nijmegen modification of the Bethesda assay or the assay employed in the respective local laboratory) at any time prior to screening
- •The subject has a history of allergic reaction, eg, anaphylaxis, following exposure to factor IX concentrate(s)
- •The subject has a known hypersensitivity to hamster proteins
- •The subject has evidence of a thrombotic disease, fibrinolysis or disseminated intravascular coagulation (DIC)
- •The subject is scheduled for elective surgery, unless the surgery is medically required within the anticipated study period
- •The subject has an abnormal renal function (serum creatinine > 1.5 times the upper limit of normal)
- •The subject has severe chronic liver disease as evidenced by, but not limited to, any of the following: International Normalized Ratio (INR) exceeding the upper limit of normal (ULN), hypoalbuminemia, portal vein hypertension including presence of otherwise unexplained splenomegaly and history of esophageal varices
- •The subject has active hepatic disease with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels >= 5 times the upper limit of normal. During the study, subjects with chronic hepatitis B or C may have fluctuations of up to 5 times the upper limit of normal but will not require discontinuation.
- •The subject has been diagnosed with an inherited or acquired hemostatic defect other than hemophilia B
- •The subject's platelet count is < 100,000/mL
- •The subject has a clinically significant medical, psychiatric, or cognitive illness, or recreational drug/alcohol use that, in the opinion of the investigator, would affect subject's safety or compliance
- •The subject is currently receiving, or is scheduled to receive during the course of the study, an immunomodulating drug other than anti-retroviral chemotherapy (eg, α-interferon, corticosteroid agents at a dose equivalent to hydrocortisone greater than 10 mg/day)
- •The subject is unwilling to consider further participation in BAX 326 (rFIX) pivotal study 250901 or BAX 326 pediatric study
- •The subject has participated in another investigational study within 30 days of enrollment or is scheduled to participate in another clinical study involving an investigational product (IP) or investigational device during the course of this study
- •The subject is a member of the team conducting this study or is in a dependent relationship with one of the study team members. Dependent relationships include close relatives (ie, children, partner/spouse, siblings, parents) as well as employees of the investigator or site personnel conducting the study.
结局指标
主要结局
Hemostatic Efficacy
时间窗: 28 months
* Number of IMMUNINE infusions required to achieve adequate hemostasis for each bleeding episode * Overall hemostatic efficacy rating of IMMUNINE for all bleeding episodes (scale of excellent, good, fair, none) * Annualized bleeding rate * Consumption of IMMUNINE * Number of infusions per month and per year (prophylaxis and on-demand) * Weight-adjusted consumption of IMMUNINE per event (prophylaxis, on-demand), per month and per year
次要结局
未报告次要终点
研究者
研究点 (33)
Loading locations...
相似试验
终止
3 期
Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia BHemophilia BNCT01271868Medexus Pharma, Inc.9
已完成
1 期
Phase I/II Study of Monoclonal Factor IX Concentrate for Factor IX DeficiencyFactor IX DeficiencyHemophilia BNCT00004801National Center for Research Resources (NCRR)3
进行中（未招募）
不适用
IMMUNINE - A Clinical Study with IMMUNINE (A Purified Factor IXConcentrate Virus-Inactivated) in Previously Treated Patients withSevere or Moderately Severe Hemophilia B Who are Planned to Enter theBAX 326 Study (250901, Investigating a new Factor IX Product)to expose up to 50 patients aged 12-64 years, and approximately 20 patients up to 11 years of age with severe or moderately severe hemophilia B to IMMUNINE for a period of approximately 20 to 50 exposure days (EDs) prospectively document the exposure days (EDs) and development of factor IX (FIX) inhibitionors if any, while receiving prophylactic treatment so that these patients can transition into the BAX 326 pivotal or pediatric study evaluating a new rFIX.MedDRA version: 14.0Level: LLTClassification code 10060614Term: Hemophilia B (Factor IX)System Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2009-016719-39-PLBaxter Innovations GmbH70
进行中（未招募）
不适用
IMMUNINE - A Clinical Study with IMMUNINE (A Purified Factor IX Concentrate Virus-Inactivated) in Previously Treated Patients with Severe or Moderately Severe Hemophilia B Who are Planned to Enter the BAX 326 Study (250901, Investigating a new Factor IX Product)EUCTR2009-016719-39-CZBaxter Innovations GmbH70
进行中（未招募）
不适用
IMMUNINE – Purified Factor IX Concentrate Virus-Inactivated: A Phase IV, Prospective, Open-label Multicenter Study to Prospectively Document the Exposure of IMMUNINE and to Monitor FIX Inhibitors in Previously Treated Patients with Severe (FIX level < 1%) or Moderately Severe (FIX level =2%) Hemophilia B Who are Planned to Enter BAX 326 Study 250901 to investigate a New Recombinant FIX Concentrate - IMMUNINE Pre-Treatment StudyEUCTR2009-016719-39-BGBaxter Innovations GmbH50